https://menafn.com/1100133864/Bridge-Biotherapeutics-Announces-the-IND-Clearance-of-BBT-176-an-EGFR-TKI-for-NSCLC-in-South-Korea
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea
| MENAFN.COM
(MENAFN - PR Newswire) Following the US FDA's IND clearance,South Korea's MFDS cleared the IND application of BBT-176, submitted in December 2019 BBT-176 will be the company's first drug candidate to launch clinical studies in South Korea In the second half of this year, the companyis expected...